TB-500

Thymosin beta-4 is a naturally occurring protein with a role in actin regulation. TB-500 is a synthetic peptide associated with an active region of it — related, but not the same molecule, and that distinction gets lost constantly in marketing copy.

Most of what circulates about this compound comes from preclinical work — cell and animal models. What research explores in that setting does not transfer automatically to people, and the gap between a promising animal result and an established human option is where almost all of the marketing in this category lives.

Searches for benefits here are almost always about recovery and tissue repair, driven by preclinical findings around cell migration and wound models.

The honest position is the same as for BPC-157: that work is real, it is largely in animals and cell models, and it does not establish outcomes in people. There is no substantial human trial evidence supporting the claims made in the marketplace.

If you have a specific injury, that injury deserves a diagnosis and a rehabilitation plan from someone qualified to give you one.

There is no approved label for TB-500, so there is no regulator-reviewed account of adverse effects. That absence is the finding — not a gap we can fill with a plausible-looking list.

Add to that the sourcing problem below, and a further difficulty appears: if a vial's actual contents are uncertain, then any effect experienced cannot be confidently attributed to the labelled substance in the first place.

What can be said is where the regulator locates the concern. FDA has placed this substance in the bulk-substances category reserved for those that may present significant safety risks, and its stated reasoning is specific: compounded drugs containing thymosin beta-4 fragment may pose a risk of immunogenicity for certain routes of administration because of the potential for aggregation as well as peptide-related impurities.

The agency goes further and says it has not identified any human exposure data for drug products containing thymosin beta-4 fragment, and that it lacks important information about safety issues raised by the substance, including whether it would cause harm if administered to humans. That is an unusually blunt statement of an evidentiary void, and it is the most accurate summary of the side-effect position available.

The regulatory position on this compound is actively moving, which is worth knowing before reading any older account of it as settled.

TB-500-related bulk drug substances — both the free base and the acetate — were on the agenda of the Pharmacy Compounding Advisory Committee meeting held in July 2026, as substances being considered for inclusion on the 503A Bulks List. The use FDA reviewed for them was wound healing. BPC-157, KPV and MOTs-C were considered at the same meeting.

Inclusion on that list would mean the substance could lawfully be used in 503A compounding. Exclusion would mean the opposite.

The meeting has since taken place and the position is unchanged. Advisory committee recommendations are non-binding, the 503A Bulks List is amended only through notice-and-comment rulemaking, and TB-500 does not appear on that list as fetched on 2026-08-23. Trade coverage reported a favourable recommendation on day one of the meeting. Anyone describing this compound's status as settled — in either direction — is still ahead of the regulator, and our account of exactly what the vote did is on the peptide legal-status page.

Material sold online is generally offered as a research chemical for laboratory use. That is not a formality. It means the vial was not prepared to pharmaceutical manufacturing standards, was not tested for identity and purity the way a prescription medicine is, and was not intended to be put into a person.

Independent testing of this market has repeatedly found products that do not match their labels — wrong quantity, wrong substance, or contaminants. You cannot assess any of that by looking at the vial.

A compounding pharmacy working on a prescriber's order is a different situation with real oversight attached. If someone is offering you a compounded preparation, ask which pharmacy, in which state, and under what authority for this specific substance.

Get the underlying problem properly assessed. Recovery questions usually have established answers with real human evidence behind them, and those are worth working through first.

Dosing is determined by a licensed provider.

How we verify providers

• FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — retrieved 2026-08-06
• FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — retrieved 2026-08-06
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — retrieved 2026-08-06
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — retrieved 2026-08-23
• WADA — The Prohibited List — retrieved 2026-08-13